SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

(NASDAQ:SIGA) SIGA Technologies announced that Dennis Hruby, Ph.D., Executive Vice President and Chief Scientific Officer, will retire effective today after more than 30 years with the company. Dr. Hruby joined SIGA in 1996 as a senior scientific advisor, became Vice President of Research in 1997, and has served as Chief Scientific Officer since 2000. During his tenure, Dr. Hruby led the development of tecovirimat, which is now marketed as TPOXX®. TPOXX received U.S. FDA approval for its oral formulation in 2018 and for its intravenous formulation in 2022. The product has also received regulatory approvals in Canada, the European Union, the United Kingdom, and Japan. TPOXX was the first antiviral therapeutic approved for the treatment of smallpox. The product has been sold to more than 30 countries. Diem Nguyen, Chief Executive Officer, stated that Dr. Hruby's 30 years of service reflect a distinguished career defined by scientific rigor, vision, and commitment to public health, and credited him with playing an instrumental role in the development of TPOXX. Dr. Hruby expressed pride in the company's achievements, noting that when he joined there was no antiviral treatment for smallpox, and now there is one that is approved, stockpiled, and ready if needed. Following his retirement, Dr. Hruby will continue to support SIGA in an advisory capacity.

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

(NASDAQ:SIGA) SIGA Technologies, Inc. reported financial results for the three and six months ended June 30, 2026.